Poster Session A

Poster Session A
Friday, February 25
1:00 p.m.-4:00 p.m.

In alphabetical order, not board assignment order

• Akt activity mediates reversible dormancy in patient ascites-derived epithelial ovarian cancer spheroids. Rohann JM Correa¹, Monique Bertrand¹, Michel Prefontaine¹, Akira Sugimoto¹, Trevor G. Shepherd¹, Gabriel E. DiMattia². ¹Schulich School of Medicine & Dentistry, London, ON, Canada, ²London Regional Cancer Program, London, ON, Canada
• AKT inhibitors cause spontaneous apoptosis EBV immortalized B-lymphocytes. Gwen Taylor, Adam Rosendorff. University of Pittsburgh, Pittsburgh, PA
• Antilymphangiogenic properties of mTOR inhibitors in a HNSCC model of regional metastasis. Oleksandr Ekshyyan, Michael A. Brodt, Matthew C. Raley, Tara N. Moore-Medlin, Fleurette Abreo, Gloria Caldito, Jonathan Steven Alexander, Cherie-Ann O. Nathan. Louisiana State University Health Sciences Center, Shreveport, LA
• BEZ235 a novel PI3K/mTOR inhibitor prevents PI3K signaling and promotes apoptosis in HER2+ breast tumor cells. Pradip De, Yuliang Sun, Hui Wu, Nandini Dey, Brian Leyland-Jones. Emory University, Atlanta, GA
• Biological effects of metformin in early-stage breast cancer. Ryan J.O. Dowling¹, Pamela J. Goodwin², Vuk Stambolic¹, Saroj Niraula³, Martin C. Chang⁴, Susan J. Done³, Marguerite Ennis⁵, Samantha Beddows⁶, Nicky Hood⁶, Wey Leong³, Jaime M. Escallon⁶. ¹Ontario Cancer Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Mt. Sinai Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Dept. of Path. and Lab. Medicine, Mt. Sinai Hospital, Toronto, ON, Canada, ⁵Applied Statistician, Markham, ON, Canada, ⁶Mt. Sinai Hospital, Toronto, ON, Canada
• Combined deletion of Pten, Trp53 and Rb1 induced astrocytomas within and outside of proliferative niches in the mature brain. Sherri L. Rankin, Lionel M.L. Chow, Raelene Endersby, Xiaoyan Zhu, Junyuan Zhang, Chunxu Qu, David W. Ellison, Suzanne J. Baker. St Jude Children's Research Hospital, Memphis, TN
• Combined inhibition of HER2 and PI3K overcomes resistance to HER2-directed therapies in breast cancer cells. Brent N. Rexer, Carlos L. Arteaga. Vanderbilt University School of Medicine, Nashville, TN
• Concurrent administration of doxorubicin and lapatinib worsens doxorubicin-induced cardiac dysfunction in mice. David Goukassian, Xinhua Yan, Sharath Sasi, Juyong Lee, Daniela Budiu, Christopher Lawson, Michael Maysky, Lynn Hlatky, Joseph Carrozza, James P. Morgan. St. Elizabeth's Medical Center, Brighton, MA
• Cooperation between PIK3CAH1047R and BRAFV600E in lung tumorigenesis and melanoma. Martin McMahon¹, Christy Trejo¹, Victoria Marsh¹, Shoshana Greenberg¹, Wayne Phillips². ¹University of California, San Francisco, CA, ²Peter MacCallum Institute, Melbourne, Victoria, Australia
• Development and characterization of a breast cancer cell line with acquired resistance to rapamycin. Farrell C. Adkins, Funda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, Chandeshwar Sharma, Gopal Singh, Kim-Anh Do, Ana Maria Gonzalez-Angulo, Gordon B. Mills, Mien-Chie Hung. University of Texas MD Anderson Cancer Center, Houston, TX
• Different efficacy of combining the dual PI3K/mTOR inhibitor or pure PI3K inhibitor with radiotherapy in hepatocellular carcinoma. Jason Chia-Hsien Cheng, Yun-Pei Chuang, Ann-Lii Cheng. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
• Discovery of PIK3CA mutation and transcriptional gene signature as determinants of antitumor activity for novel class I PI3K inhibitor CH5132799. Osamu Kondoh, Yuko Aoki, Hiroshi Tanaka, Shouichi Metsugi, Miyuki Yoshida, Hiromi Tanimura, Kiyoaki Sakata, Toshihiko Fujii, Jun Ohwada, Nobuya Ishii. Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan
• Disruption of Abi1/Hssh3bp1 expression leads to prostatic intraepithelial neoplasia in conditional Abi1/Hss3hbp1 KO mice. Xiaoling Xiong¹, Anna Chorzalska¹, Julie White², Patrycja M. Dubielecka¹, Cyrus V. Hedvat², Jason Koutcher², Janet Sawicki³, Leszek Kotula¹. ¹New York Blood Center, New York, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY, ³Lankenau Institute for Medical Research, Wynnewood, PA
• Dose-dependent effects of rapamycin on the functional proteomic profile of rapamycin-resistant versus rapamycin-sensitive in vivo breast cancer models. Priscilla F. McAuliffe, Argun Akcakanat, Chandeshwar Sharma, Huiqin Chen, Gopal Singh, Kim-Anh Do, Ana M. Gonzalez-Angulo, Gordon B. Mills, Funda Meric-Bernstam. University of Texas MD Anderson Cancer Center, Houston, TX
• Downregulation of mTOR cellular signaling by short chain fatty acids: Nutrient targeting mTOR signaling. Yong Tang, Daotai Nie. Southern Illinois University School of Medicine and Simmons Cancer Institute, Springfield, IL
• Effects of rapamycin and doxorubicin combination on growth and gene expression profile of human HER-2-expressing breast epithelial cell lines. Adriana Priscila Trapé¹, Maria Lúcia Hirata Katayama¹, Rosimeire Aparecida Roela¹, Leandro Araújo Lima², Helena Paula Brentani¹, Maria Mitzi Brentani¹. ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital AC Camargo, São Paulo, Brazil
• Efficacy of sunitinib-everolimus sequential treatment in an orthotopic mouse renal cell carcinoma model. Zenta Tsuchihashi¹, Ralph Graeser², Ulrike Fiedler², Norbert Esser². ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²ProQinase GmbH, Freiburg, Germany
• Evaluation of a selective PI3K inhibitor GDC-0941 alone or in combination with cytarabine for the treatment of acute myeloid leukemia. Brian D. Furmanski, Shuiying Hu, Orwick Shelley, Sharyn D. Baker. St. Jude Children's Research Hospital, Memphis, TN
• Galectin-1 interacts with class I PI3K and modulates PI3K activity in vitro. James Perry, Arnab Chakravarti, Tim Lautenschlaeger. The Ohio State University, Columbus, OH
• Genome-level expression data of colorectal cancer identify deregulation of phospholipase C isozymes within the phosphatidyl inositol signaling pathway. Stine A. Danielsen, Lina Cekaite, Rolf I. Skotheim, Ragnhild A. Lothe. Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
• Genomic profiling of ovarian tumor cell lines provides both a predictive signature of sensitivity and insight into drug resistance to PF-4691502, a dual PI3-kinase and mTOR inhibitor. Karen Elizabeth Sheppard¹, Carleen Cullinane¹, Rod Hicks¹, Grant McArthur¹, Wayne Phillips¹, Richard B. Pearson¹, Kathryn Kinross¹, Amelia Neilsen¹, Gwyn Ng¹, Margarete Kleinschmidt¹, Richard Tothill¹, Jason Ellul¹, Ross Hannan¹, James Christensen². ¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, ²Pfizer, La Jolla, CA
• HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo. Ariella B. Hanker, Cammie Rinehart, Rebecca S. Cook, Carlos L. Arteaga. Vanderbilt University, Nashville, TN
• Hormone-independent breast cancer cells hyperactivate PI3-kinase and maintain an ERα-dependent, E2F-directed transcriptional program. Todd W. Miller¹, Mitch Dowsett², R. Adam Smith¹, H. Charles Manning¹, William R. Miller³, Yu Shyr¹, Carlos L. Arteaga¹, Justin M. Balko¹, Bryan T. Hennessy⁴, Ana M. González-Angulo⁴, Gordon B. Mills⁴, Emily M. Fox¹, Zara Ghazoui², Anita Dunbier², Helen Anderson². ¹Vanderbilt University, Nashville, TN, ²Breakthrough Breast Cancer Research Centre, London, England, ³University of Edinburgh, Edinburgh, United Kingdom, ⁴M.D. Anderson Cancer Center, Houston, TX
• Identification of PHLPP as a tumor suppressor reveals the role of feedback compensation in PTEN-mutant prostate cancer progression and therapy. Muhan Chen¹, Danielle M. Grace¹, Jernej Murn¹, Chris Sander², William L. Gerald², Carlos Cordon-Cardo³, Alexandra C. Newton⁴, Brett S. Carver², Lloyd C. Trotman¹, Christopher P. Pratt¹, Martha E. Zeeman¹, Nikolaus Schultz², Barry S. Taylor², Audrey O'Neill⁴, Mireia E. Castillo-Martin³, Dawid G. Nowak¹, Adam Naguib¹. ¹Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ²Memorial Sloan-Kettering Cancer Center, New York, NY, ³Columbia University, New York, NY, ⁴University of California San Diego, La Jolla, CA
• Identification of STAT3 as a necessary component of PI3K-mediated oncogenic transformation. Jonathan Ross Hart, Lujian Liao, Lynn Ueno, John R. Yates, III, Peter K. Vogt. The Scripps Research Institute, La Jolla, CA
• In vitro and in vivo characterization of novel and selective PDK1 inhibitors for the treatment of cancer. Nuzhat Pathan, Angela Pasis, Betty Tam, Krista Taylor, Lihong Sun, Kandasamy Hariharan, Leona Ling, Mitchell Reff, Ingrid B.J.K Joesph, Nicki English, Monica Holcomb, Alyssa Ramos-Chavez, Antonio Boccia, Grace Yco, Cyrus Vitata, James Games, Tony Li. Biogen Idec Inc, San Diego, CA
• Induction of lipogenesis by AKT2 is necessary for tumor development in the liver specific Pten deletion model. Vivian Galicia, Lina He, Ni Zeng, Bangyan Stiles. University of Southern California, Los Angeles, CA
• Inhibition of CXCL12/CXCR4-mediated cell migration by targeting mTOR pathway in human gastric carcinoma cells. Guang Chen, Xiang Wang, Si-Meng Chen, Jian Ding, Ling-hua Meng. Shanghai Institute of Materia Medica, Shanghai, China
• Inhibition of mTOR synergizes with the antiproliferative effects of pyruvate kinase inhibitor in breast cancer cells: Metabolic pathway in tumor cells meets survival pathway. Nandini Dey, Mark Baillie, Hui Wu, Yuliang Sun, Pradip De, Brian Leyland-Jones. Emory University, Atlanta, GA
• Investigating the role of mTORC1 and mTORC2 inhibition in renal cell carcinoma (RCC). Sean T. Bailey. University of North Carolina, Chapel Hill, NC
• Loss of androgen receptor transcriptional regulation of Nrdp1, a negative regulator of ErbB3, results in castration resistant growth of prostate cancer cells. Liqun Chen, William H. Fry, Rosalinda M. Savoy, Maitreyee Jathal, Swagata Bose, Benjamin A. Mooso, Sheetal Singh, Kermit L. Carraway, III, Paramita M. Ghosh. University of California Davis School of Medicine, Sacramento, CA
• Loss of PTEN and nuclear expression of EGR1 in acquired resistance to gefitinib/erlotinib in lung cancer cells. Mayumi Ono. Kyushu University, Fukuoka, Japan
• Loss of PTEN cooperates with TGF-β receptor inactivation to promote intestinal tumor progression. Ming Yu, Patty Trobridge, Samornmas Kanngurn, Shelli M. Morris, Sue Knoblaugh, William M. Grady. Fred Hutchinson Cancer Research Center, Seattle, WA
• Mechanistic insight into the synergistic action of combining mTOR and histone deacetylase (HDAC) inhibitors for treatment of multiple myeloma. John Kyle Simmons, Jyoti Patel, C. Ola Landgren, Beverly A. Mock, Aleksandra M. Michalowski, Patrick Sullivan, Bih-Rong Wei, R. Mark Simpson, W. Michael Kuehl, Lihui Ou, Natasha J. Caplen, Shuling Zhang. National Cancer Institute, Bethesda, MD
• Mislocalization of β-TrCP1 in glioblastoma uncouples negative feedback between PHLPP1 and Akt. Noel A. Warfel¹, Matt Niederst¹, Paul Brennan², Margaret Frame², Alexandra Newton¹. ¹University of California, San Diego, La Jolla, CA, ²University of Edinburgh, Edinburgh, United Kingdom
• mTOR as a determinant of the synergistic interaction of MEK and PI3K inhibitors. Emma J. Cox, Suzanne Kyle, Gary S. Beale, Maxwell J. Ross, David R. Newell. Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle-Upon-Tyne, United Kingdom
• mTOR complexes differentially modulate proapoptotic MST1 and MST2 kinase signaling in prostate cancer. Filiz Kisaayak Collak, Hyung L. Kim, Leland W.K. Chung, Bekir Cinar. Cedars-Sinai Medical Center, Los Angeles, CA
• mTOR is a key mediator of progression of prostate cancer to hormone independence. Shruti A. Apte, David Cavazos, Linda deGraffenried. University of Texas, Austin, TX
• mTOR kinase domain phosphorylation promotes mTORC1 function. Bilgen Ekim¹, Brian Magnuson¹, Hugo Acosta-Jaquez¹, Jennifer Keller¹, Edward P. Feener², Diane C. Fingar¹. ¹University of Michigan Medical School, Ann Arbor, MI, ²Joslin Diabetes Center, Boston, MA
• mTOR signaling through S6K2 and 4EBP1 in regulation of estrogen receptor alpha phosphorylation and endocrine resistance in breast cancer. Josefine Bostner¹, Elin Karlsson¹, Hanna Westman¹, Amin Risul¹, Gizeh Péres-Tenorio², Olle Stål¹. ¹Linköping University, Linköping, Sweden, ²Burnham Institute for Medical Research, San Diego, CA
• mTORC1 and mTORC2 regulate motility and metastasis of colorectal cancer via RhoA and Rac1 signaling. Pat Gulhati¹, Tianyan Gao¹, B Mark Evers¹, Kanika Bowen², Jianyu Liu¹, Payton Stevens¹, Piotr G. Rychahou¹, Min Chen¹, Eun Y. Lee¹, Heidi L. Weiss¹, Kathleen L. O'Connor¹. ¹University of Kentucky, Lexington, KY, ²University of Texas Medical Branch, Galveston, TX
• mTORC1-driven negative feedback signaling protects HER2-HER3 tumorigenic signaling in breast cancers. Dhara N. Amin, Andrew Hsieh, Natalia Sergina, Martin McMahon, Davide Ruggero, Kevan Shokat, Mark M. Moasser. University of California, San Francisco, CA
• Mutational activation of PI3’-kinase-α dramatically accelerates BRAFV600E-induced lung tumorigenesis. Christy L. Trejo¹, Victoria Marsh¹, Shoshana Greenberg¹, Wayne Phillips², Martin McMahon¹. ¹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, ²Peter MacCallum Cancer Centre, Melbourne, Australia
• N terminal tags confer a gain of function to the catalytic subunit p110α of phosphoinositide 3-kinase (PI3K). Minghao Sun, Petra Hillmann, Jonathan R. Hart, Marco Gymnopoulos, Vogt K. Peter. The Scripps Research Institute, La Jolla, CA
• Novel, gross chromosomal structural aberrations of PTEN occur frequently in prostate cancer. Alison H M Reid¹, Sue Merson¹, Roy Vergis¹, Charles Jameson², Sara Heeboll³, Michael Borre³, Chris Parker¹, Johann de Bono¹, Colin Cooper¹, Gerhardt Attard¹, Susana Miranda¹, Ruth Riisnaes¹, Daniel Brewer¹, Jeremy Clark¹, Lucy Matthews¹, Sandra Edwards¹, Penny Flohr¹. ¹The Institute of Cancer Research, London, United Kingdom, ²Royal Marsden NHS Foundation Trust, London, United Kingdom, ³Aarhus University Hospital, Skejby, Denmark
• Opposing effects of PTEN acetylation and T366-phosphorylation in response to PI3K activation. Jorge A. Benitez, Webster K. Cavenee, Frank B. Furnari. Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA
• Palomid 529, an allosteric dual TORC1/TOR2 inhibitor of the PI3K/Akt/mTOR pathway, shows differential effects compared to TORC1 inhibition. Claudio Festuccia¹, Qin Yang², Giovanni Melillo³, Stephen Yoo⁴, Chunrong Yu⁵, Laura Benjamin⁶, K. Eric Paulson⁷, Amy S. Yee⁷, David Sherris⁸. ¹University of L'aquila, L'aquila, Italy, ²Washington University School of Medicine, St. Louis, MO, ³National Cancer Institute, Frederick, MD, ⁴National Cancer Institute, Rockville, MD, ⁵Roswell Park Cancer Institute, Buffalo, NY, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Tufts University School of Medicine, Boston, MA, ⁸Paloma Pharmaceuticals, Inc., Jamiaca Plain, MA
• Paracrine signaling through Mycn enhances tumor-vascular microenvironment in neuroblastoma. Yvan H. Chanthery, W. Clay Gustafson, William A. Weiss. University of California, San Francisco, CA
• Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Julie K. Schwarz¹, Janet Rader², Perry W. Grigsby¹, Jacqueline Payton³, Rashmi Ramachandran¹, Tao Xiang¹, Jia Yunhe¹, Phyllis Huettner³, Mark Watson¹, Buck Rogers¹, Qin Yang¹. ¹Washington University School of Medicine, St. Louis, MO, ²Medical College of Wisconsin, Milwaukee, WI, ³Alvin J. Siteman Cancer Center, St. Louis, MO
• Phospholipase D mediates nutrient input to mTORC1. Limei Xu¹, Darin Salloum¹, David Foster². ¹The Graduate Center, The City University of New York, New York, NY, ²Hunter College of the City University of New York, New York, NY
• PI3K inhibition to overcome HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Koshiro Ostubo, Ivan S. Donev, Tadaaki Yamada, Shinji Takeuchi, Seiji Yano. Kanazawa University, Kanazawa, Japan
• PI3K/AKT/mTOR inhibitors in patients with advanced solid tumors and PIK3CA mutations and/or PTEN loss. Filip Janku. University of Texas MD Anderson Cancer Center, Houston, TX
• PI3K/mTOR signaling promotes p27-dependent tumor cell motility and bone metastasis. Seth A. Wander, Dekuang Zhao, Feng Hong, Jian Qin Wei, Nanette Bishopric, Joyce M. Slingerland. University of Miami, Miami, FL
• Pik3caH1047R mutation cooperates with Pten loss to promote tumorigenesis in a novel mouse model of ovarian cancer. Kathryn M. Kinross¹, Margarete Kleinschmidt¹, Karen Montgomery¹, James Christensen², Ricky Johnstone¹, Grant McArthur¹, Wayne A. Phillips¹. ¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia, ²Pfizer, Inc., La Jolla, CA
• Prognostic value of GAL-1 gene expression in GBM patients depends on PI3K pathway activation based on an exploratory subgroup analysis of the TCGA dataset. Alexander Huebner¹, James Perry¹, Michael Siedow¹, Arnab Chakravarti², Tim Lautenschlaeger². ¹The Ohio State University Medical Center Comprehensive Cancer Center, Columbus, OH, ²The Ohio State University Medical Center, Columbus, OH
• Protein microarray analysis of disregulated signaling pathways in acute myeloid leukemia to predict the patient's responsiveness to PI3K/Akt/mTOR inhibitors. Jessika Bertacchini¹, Marianna Guida¹, Fabio Forghieri², Mario Luppi², Lance A. Liotta³, Emanuel Petricoin, III³, Benedetta Accordi⁴, Giuseppe Basso⁴, Sandra Marmiroli¹. ¹Department of Anatomy and Histology, Modena, Italy, ²Department of Oncology and Hematology, Modena, Italy, ³Center for Applied Proteomics & Molecular Medicine, GMU, Fairfax, VA, ⁴Pediatric Department of Hematology, Padova, Italy
• Quantitative measurements of HER3-PI3K complex and total PI3K p85α subunit in formalin-fixed, paraffin-embedded (FFPE) tissues using VeraTag™ immunoassays. Yining Shi, Lisa DeFazio Eli, Alicia Newton, Kristi Strommen, Ali Mukherjee, Youssouf Badal, Laurie Goodman, Steve Williams. Monogram Biosciences Inc., South San Francisco, CA
• Quantitative signaling input-output relationships from steady-state single-cell data. John G. Albeck¹, Gordon B. Mills², Joan S. Brugge¹. ¹Harvard Medical School, Boston, MA, ²University of Texas MD Anderson Cancer Center, Houston, TX
• Rapamycin exacerbated doxorubicin cardiac dysfunction in mice. Xinhua Yan. St. Elizabeth's Medical Center, Brighton, MA
• Rational combination studies of everolimus in mantle cell lymphoma. Laia Rosich, Gaë Roué, Sílvia Xargay-Torrent, Monica López-Guerra, Elías Campo, Dolors Colomer. Centro Esther Koplowitz-Hospital Clinic, Barcelona, Spain
• Regulatory loops between mTOR/S6K1 and estrogen receptor α signaling pathways. Denise Myriam Maruani, Marina K. Holz. Yeshiva University, New York, NY
• SB2343, a novel tetra-substituted purine, inhibits mTOR and PI3K equipotently, and has favorable pharmacokinetic and pharmacodynamic properties and is orally efficacious in various cancer models. Stefan Hart, Chang Kai Soh, Zahid Bonday, Kee Chuan Goh, Veronica Diermayr, Yung Kiang Loh, Chitra Amalina, Yong Cheng Tan, Bee Kheng Ng, Khalid M. Pasha, Kantharaj Ethirajulu, Meredith Williams, Brian Dymock, Jeanette Wood, Ramesh Jayaraman, Harish Nagaraj, Anders Poulsen, Stephanie Blanchard, Angeline Lee, Haishan Wang, Di Zhong Chen. S*BIO Pte Ltd, Singapore, Singapore
• Specific amino acid substitutions in mutant KRAS differentially regulate PI3K signaling and predict patient survival and response to targeted therapy. Nathan T. Ihle¹, Roy S. Herbst¹, Vassiliki Papadimitrakopoulou¹, Edward S. Kim¹, Waun K. Hong¹, Garth Powis¹, Ignacio I. Wistuba¹, J. Jack Lee¹, Lu Chen¹, Shuxing Zhang¹, Lauren A. Byers¹, John V. Heymach¹, John D. Minna², Jill E. Larsen². ¹University of Texas MD Anderson Cancer Center, Houston, TX, ²University of Texas Southwestern, Dallas, TX
• Stimulation of ErbB3 induces resistance in patients on everolimus +bicalutamide: Results from a phase II study. Leandro D'Abronzo¹, Mohana Roy², Primo Lara¹, Ralph W. deVere White¹, Chong-xian Pan¹, Paramita M. Ghosh¹. ¹University of California Davis School of Medicine, Sacramento, CA, ²VA Northern California Health Care System, Sacramento, CA. 
• Targeting FASN to circumvent tamoxifen resistance. Richa Tiwary, Weiping Yu, Bob G. Sanders, Kimberly Kline. University of Texas, Austin, TX
• Targeting PI3K/mTOR inhibitor induced survival programs abrogates resistance to cell death in ECM-attached cancer cells. Taru Muranen¹, Fabiana Morales², Laura Selfors¹, Devin Worster¹, John Albeck¹, Marcin Iwanicki¹, Gordon Mills², Joan S. Brugge¹. ¹Harvard Medical School, Boston, MA, ²University of Texas MD Anderson Cancer Center, Houston, TX
• The Akt-associated microRNAs in cancer cells. Mohit Sachdeva, Hailong Wu, Yin-Yuan Mo. Southern Illinois University School of Medicine, Springfield, IL
• The effect of AKT inhibitors and AKT knock down by siRNA on glucose uptake in cells. Kathrin Heinzmann, Yuen-Li Chung, Tatiana McHardy, John Caldwell, Ian Collins, Michael Partridge, Michelle Garrett. Institute of Cancer Research, Sutton, United Kingdom
• The role of SREBP activation downstream of mTORC1 in tumor cell metabolism. Jessica L. Yecies¹, Katrin Duevel¹, Suchithra Menon¹, Pichai Raman², Derek Yecies¹, Clary B. Clish³, Leon O. Murphy², Brendan D. Manning¹. ¹Harvard School of Public Health, Boston, MA, ²Novartis Institutes for BioMedical Research, Cambridge, MA, ³Broad Institute of MIT and Harvard, Cambridge, MA
• Translation initiation factor eIF4GI confers radioresistance to the cancer stem cell population in advanced breast cancers. Deborah Silvera, Eileen P. Connolly, Michelle E. Badura, Toni A. Venuto, Silvia C. Formenti, Robert J. Schneider. NYU School of Medicine, New York, NY
• Translational control in prostate cancer. Andrew C. Hsieh¹, Kevan M. Shokat¹, Jonathan S. Weissman¹, Christian Rommel², Davide Ruggero¹, Yi Liu², Nicholas T. Ingolia³, Merritt P. Edlind¹, Carly Christensen¹, Robert Bok¹, Kristen Scott¹, Morris E. Feldmen¹, John Kurhanewicz¹. ¹UCSF, San Francisco, CA, ²Intellikine, La Jolla, CA, ³Carnegie Institution for Science, Baltimore, MD
• Using time-dependent cellular response profiles to screen and identify potentially novel PI3K inhibitors. Li (Leyna) Zhao¹, Peter K. Vogt², Yama Abassi¹, Xiaobo Wang¹, Xiao Xu¹. ¹Acea Biosciences Inc., San Diego, CA, ²The Scripps Research Institute, La Jolla, CA